Introduction
Manipulation of signal transduction pathways for disease management has recently attracted considerable attention (reviewed in Levitzky, 1996 Levitzky, , 1997 . So far small molecules have been most successful, but macromolecules, such as antisense nucleotides and RNA to signaling molecules and ribozymes, can be used as well. An interesting approach makes use of a dominant-negative protein to speci®cally down-regulate the signal transduction pathway to which it belongs by sequestering the cognate interacting protein(s).
A major target for the therapy of proliferative disorders is represented by the ras proto-oncogenes and their encoded proteins, which are small guanine nucleotide binding proteins acting as molecular switches in cell proliferation and signal transduction (Barbacid, 1987; Lowy and Wilumsen, 1993) . In humans three major ras genes exist, H-ras, K-ras and N-ras. Each of the ras-encoded proteins, which we will refer to collectively as p21 ras , can work as an oncoprotein upon mutational activation. Activated ras genes have been found in a great variety of human tumors. The highest incidence of ras mutations can be found in pancreas (90%), colon (50%) and lung (30%) adenocarcinomas, as well as in thyroid tumors (50%) and myeloid leukemias (Barbacid, 1987; Bos, 1988 Bos, , 1990 . Within cells, ras proteins exist in either a GTPó r a GDP´bound form. Ras proteins are endowed with a low intrinsic GTPase activity and like all GTPases can go through a cycle of reactions. Oncogenic versions of p21 ras are found mostly in the GTP´bound form either because of a reduced GTPase activity or because of an increased GDP/GTP exchange. The cellular level of the active, GTP´bound form results from the balance of the competing activity of GTPase Activating Proteins (GAP) and Guanine nucleotide Exchange Factors (GEF) (reviewed in Bollag and McCormick, 1991; Feig, 1994; Lowy and Willumsen, 1993; Boguski and McCormick, 1993; Campbell et al., 1998) . In mammalian cells two classes of ras-speci®c GEF have been identi®ed. One class is mostly brain-speci®c and has been called CDC25 Mm , Ras Grf, hGRF55 by various groups (Martegani et al., 1992; Shou et al., 1992; Schweighoer et al., 1993; Wei et al., 1993 Wei et al., , 1994 Sturani et al., 1997) . The other class is expressed ubiquitously and is called Sos Buday and Downward, 1993; Guerrero et al., 1996) . Both GEFs are large, multi-domain proteins, whose catalytic domains are approximately 70% homologous. The structural organization of the two GEF classes re¯ects the involvement in dierent signal transduction pathways. Sos has been shown to work downstream of tyrosine kinase receptors Buday and Downward, 1993; Li et al., 1993) , while CDC25 Mm may interact with trimeric G protein-coupled receptors (van Biesen et al., 1995; Zippel et al., 1996; Mattingly and Macara, 1996) and play a role in synaptic transmission and long-term memory (Brambilla et al., 1997) . Deregulated expression of both GEF classes has been shown to induce cell transformation in dierent experimental systems (Zippel et al., 1994; Egan et al., 1993) .
A GEF mutant with dominant-negative properties has been recently isolated (Vanoni et al., 1999) . The mutant carries a single missense mutation at codon 1056, resulting in a tryptophan/glutamate substitution. We will refer to the mutant as GEF
W1056E
. The dominant-negative mutant GEF is able to eciently displace wild-type GEF from p21 ras and originates a stable ras/GEF binary complex, given the strongly reduced anity of the nucleotide-free ras/GEF complex for the incoming nucleotide. We show here that this`ras-sequestering property' can be utilized to attenuate ras signal transduction pathways in mouse ®broblasts expressing activated ras. Plasmids expressing GEF mutants were introduced in k-ras transformed ®broblasts and stable transfectants selected. In these cells, over-expression of the dominant negative GEF W1056E strongly reduces intracellular ras´GTP levels and results in reversion to wild-type phenotype on the basis of morphology, cell cycle, anchorage independent growth and ability to form tumors in nude mice. The possibility to use molecules derived from dominant negative ras-speci®c GEFs to down-regulate tumor growth in vivo is discussed.
Results
The dominant-negative GEF W1056E down regulates ras´GTP levels in ras-transformed mammalian fibroblasts
We de®ne mutant GEF W1056E as a dominant-negative because in vitro it eciently displaces wild-type GEF from p21 ras (Vanoni et al., 1999) . A stable ras/GEF binary complex is originated because of the strongly reduced anity of the nucleotide-free ras/GEF complex for the incoming nucleotide. Expression of mutant GEF W1056E inhibited expression of a fos-luciferase reporter gene, both in serum-starved cells and in cells stimulated with PDGF (Vanoni et al., 1999) . Expression of GEF W1056E was similarly able to down-regulate fos-luciferase stimulated by simultaneous cotransfection with a plasmid expressing the oncogenic ras variant ras leu61 (data not shown). Since fos-luciferase activity is about 20 times higher in ®broblasts expressing oncogenic ras than in untransfected ®broblasts, these results indicate that the mutant GEF W1056E may potentially counteract phenotypes derived from oncogenic activation of p21 ras . In order to further evaluate the biological eects of GEF W1056 expression in murine ®broblasts transformed by oncogenic ras, the plasmid encoding the dominant negative GEF W1056E was stably transfected in murine NIH3T3 ®broblasts transformed with oncogenic k-ras (226.4.1 cells) and the level of p21 ras´G TP was examined. As a control, 226.4.1 cells were also transfected with a pcDNA3 plasmid expressing a recessive negative GEF mutant, GEF
W1056A
. GEF W1056A was chosen as a control because it is mutated in the same position as the dominant negative mutant, yet it shows no dominant negative properties either in vitro or in vivo (Vanoni et al., 1999) . Expression of the CDC25 Mm -GEF and the level of GTP´bound p21 ras were evaluated on selected clones. Figure 1 presented a more or less pronounced reversion of the transformed phenotype, which becamē at and very similar to that of the parental NIH3T3 cell line. Cells transfected with the recessive-negative GEF W1056A mutant behaved as cells transfected with the empty pcDNA3 vector, indicating that reversion to thē at phenotype was not simply due to over-expression of a non-functional GEF molecule. Mm protein (upper panels) and p21 ras´G TP levels (lower panels) in untransfected NIH3T3 and 226.4.1 and 226.4.1 clones expressing the recessivenegative GEF W1056A (clone WA.10) or the dominant-negative GEF W1056E (clone WE.5). The CDC25 Mm protein was identi®ed by immunoprecipitation followed by immunoblotting using antiRas-GRF C-20 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) directed against the CDC25 Mm catalytic domain. Ras´GTP was identi®ed by speci®c binding to RBD-bound Glutathione-Sepharose followed by immunoblotting of the bound proteins. The ras protein was detected by Western blotting, using as primary antibody anti-k-ras F234 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
To further characterize the biological eect of the dominant-negative GEF on cell proliferation, we investigated whether expression of the dominantnegative GEF W1056E could revert anchorage-independent growth (i.e. ability to form colonies in soft agar) of 226.4.1 cells. In order to investigate cell cycle parameters, the transfected cells were then double stained with BrdU/ PI and a¯ow cytometric analysis was performed. Figure 4 shows a representative analysis of distribution of the cell cycle phases in control NIH3T3 (panels A ± C), 226.4.1 (panels D ± F), WE.5 (panels G ± I) and WA.10 (panels J ± L) cells. Cells were serum-starved for 18 h and re-fed with 10% serum at time 0. In serum-starved cells (0 h, panels A,D,G,J) the distribution of cell cycle phases was comparable between 226.4.1 cells transfected with the dominantnegative GEF W1056E (WE.5 clone) and non-transformed NIH3T3 (with 496% of cells in G0/G1 and about 3% in S-G2/M), whereas a lower percentage of cells in G0/G1 (about 80%) and an increased percentage of cells in S-G2/M (about 20%) was present in both parental 226.4.1 and 226.4.1 expressing the recessive negative GEF W1056A (WA.10 clone). In growing cells, i.e. 36 h after serum addition (panels B,E,H,K), all the cells had comparable cell cycle phase distribution. After 72 h in serum-containing media, cells were approaching con¯uence (panels C,F,I,L). WE.5 cells comparably to non-transformed NIH3T3 showed a high percentage of cells in G0/G1 phase (about 90%) probably due to a contact inhibition phenomenon. Once again 226.4.1 and WA.10 cells behave similarly, both showing a lower percentage of cells in G0/G1 (60 ± 70%).
Interestingly, one of the clones transfected with dominant-negative GEF showed a substantial dierence in cell cycle parameters. In fact, in the DN.4 clone which had the same characteristics of transformation reversion shown for WE.5 cells (not shown) DNA endoreduplication was observed. Taken together, these results indicate that the main growth characteristics of transformed cells (anchorageindependent growth ability, serum independence and contact inhibition loss) are completely reverted in cells expressing the dominant-negative GEF. Moreover, in some cases such reversion is accompanied by DNA endoreduplication. No apoptosis was observed in any of transfected clones (data not shown).
In order to further evaluate the biological eects of the expression of the CDC25 MmW1056E in transformed ®broblasts, we tested whether expression of GEF Oncogene A dominant-negative GEF reverses neoplastic phenotype P Bossu Á et al (9.5+1.4 and 13.9+2.8 days, respectively). The two mice (out of ®ve) injected with the higher inoculum of 226.4.1 cells expressing the dominant-negative GEF W1056E who eventually formed a tumor, had a latency of 26 and 31 days, respectively. Mice with more aggressive tumors and lower latency times, as expected, showed lower survival times (Table 1) . This is also evident by calculating the mean of tumor growth.
The growth kinetics calculated on the basis of tumor size, in 226.4.1, WA.10 and WE.5 inoculated mice are similar. In keeping with tumorigenicity and survival data, an evident shift of tumor growth curve was observed in the two tumor-bearing mice (out of ®ve) inoculated with 2.5610 5 WE.5 cells (Figure 6 ). The injection of cells obtained by transfection of 226.4.1 with empty pcDNA3 gave identical results to that Figure 4 Eect of expression of the recessive-negative GEF W1056A (clone WA.10) or the dominant-negative GEF W1056E (clone WE.5) on cell cycle distribution. Cells were stained with FITC-antiBrdU to detect BrdU incorporation (vertical axis) and propidium iodide to detect total DNA (horizontal axis). The R1, R2 and R3 boxes represent G0/G1, S (i.e. incorporating BrdU) and G2+M cells, respectively. Samples were collected in serum-starved cells (0 h, panels A,D,G,J), in growing cells, i.e. 36 h after serum addition obtained with non-transfected 226.4.1 or with WA.10. Experiments performed with the endoreduplicating DN.4 cell line gave results comparable to those obtained with the WE.5 line (data not shown).
In conclusion these results indicate that expression of mutant GEF CDC25 MmW1056E induces reversion of growth characteristics in ras-transformed mammalian ®broblasts. Preliminary evidence have also been presented that the mutant GEF CDC25 MmW1056E delays ras-mediated tumor formation in xenotransplants, although eventually tumors characterized by longer latency and slower growth rate are formed in 40% of the animals.
Discussion
Dominant-negative mutants have become increasingly popular as molecular tools in the study of signal transduction pathways. We recently described dominant-negative ras-speci®c GEF mutants. In vitro, mutant GEF W1056E proteins are catalytically inactive, able to eciently displace wild-type GEF from p21 ras and originate a stable ras/GEF binary complex due to strongly reduced anity of the nucleotide-free ras/GEF complex for the incoming nucleotide (Vanoni et al., 1999) . Here we show that stable expression of this dominant negative GEF molecule in murine NIH3T3 ®broblasts transformed by the activated k-ras oncogene eectively reverts the transfected cells to normal phenotype.
Evidence for the speci®city of the repressing of the transformed phenotype by the dominant-negative GEF W1056E mutant is many-fold. First of all, when a recessive-negative mutant, whose mutation aects the same residue, GEF W1056A , was stably transfected in the same cells, no phenotypic eect could be detected, thus ruling out the possibility that inhibition of the transformed phenotype was due to overexpression of a non-functional GEF. We could also show a signi®cant reduction of the intracellular ras´GTP level. In keeping with the ras-sequestering property displayed in vitro by the puri®ed GEF W1056E catalytic domain (Vanoni et al., 1999) , this ®nding indicates that the dominant-negative GEF can eciently down-regulate intracellular p21
ras´G TP levels in transformed cells.
The main growth properties of k-ras transformed ®broblasts (anchorage-independent growth ability, serum independence and contact inhibition loss) are completely reverted in cells expressing the dominantnegative GEF
W1056E
. This ®nding, implies that ras pathway is down-regulated, but not to a point where all ras molecules are sequestered in nucleotide-free form, since a total shutting-o of the system would be lethal. Dierent extracellular signal-stimulated pathways converge at ras; in turn ras action is mediated through interaction with multiple eectors (see Campbell et al., 1998 and Zohn et al., 1998 for recent reviews). More and more evidence is accumulating that both regulators and eectors of the ras proteins can interact and/or compete with each other and for ras binding (Giglione and Parmeggiani, 1998; Anborgh et al., 1999) . Thus, the intracellular eect of a dominantnegative mutant will strongly depend on the relative concentration ± and potency ± of regulators and eectors.
In our experiments, reversion of the transformed phenotype in ®broblasts expressing the dominantnegative mutants was not due to increased apoptosis, but in some of the isolated clones it was accompanied by DNA endoreduplication. Within the resolution of our experiments, the clone showing DNA endoreduplication was undistinguishable from other clones expressing the dominant-negative GEF W1056E for all of the tested parameters. We do not know why DNA endoreduplication takes place in some cell lines expressing the dominant negative GEF W1056E and not in others. Dierent cell cycle targets for the ras pathway have been identi®ed (reviewed in Downward, 1997; Kerkho et al., 1998) . Several lines of evidence show that the eect of ras activation on mammalian cell proliferation is dependent on the allelic state of cell cycle regulating proteins, such as inhibitors of cyclin dependent kinases. For instance, it has been shown that loss of the G1 cyclin ± dependent kinase inhibitor INK4a can cooperate with ras activation in melanoma pathogenesis (Chin et al., 1997) . Disruption of p53 or the p16 INK4A /pRb pathway in rodent cells has also been shown to be very eective at abrogating premature rasinduced senescence (Serrano et al., 1997) .
Transmission of the ras signal to the cell cycle machinery is dependent on a functional retinoblastoma . Cells were stained with FITC-antiBrdU to detect BrdU incorporation (vertical axis) and propidium iodide to detect total DNA (horizontal axis) Oncogene A dominant-negative GEF reverses neoplastic phenotype P Bossu Á et al protein (pRb) (Peeper et al., 1997) . Physiological levels of the cyclin dependent inhibitor p21 slow down mostly the G1/S transition in cells with a functional pRb, while cells depleted of pRb arrest mostly at G2/M. DNA endoreduplication takes place only in pRbnegative cells, suggesting that a functional pRb protein may be necessary to prevent DNA replication in cells arrested in the G2 phase by the p21 inhibitor of cyclin dependent kinases (Niculescu et al., 1998) . It has been suggested that p21 may promote a transient pause late in G2 contributing to the implementation of late cell cycle checkpoint controls (Dulic et al., 1998) . Cells lacking the p21 checkpoint continue to undergo rounds of DNA synthesis in the absence of mitosis, culminating in polyploidy and programmed cells death (Waldman et al., 1997) . The DNA endoreduplication observed in cells expressing the dominant-negative GEF may ®t well within this scenario.
Although preliminary, the results obtained with xenotransplants in nude mice are encouraging for potential application, since they suggest that the loss of the transformed phenotype induced by the dominant negative GEF in vitro is accompanied by a reduced ability of the transfected cells (WE.5 and DN.4 clones) to induce tumors in nude mice. The observation that tumors eventually formed in some animals (although with a major delay when compared to cells transfected with the empty vector or the recessive-negative control) needs further investigation. The observed heterogeneity might be due to development of mutations that allow ras-independent tumor growth (see for instance Aftab et al., 1997; Thomas and Hall, 1997) , as well as to loss or inactivation of the dominant-negative protein. It is worth noting that in HT1080 cells and colon carcinoma cell lines loss of the mutated N-ras or kras gene resulted in reversion of in vitro growth parameters, with the mutated cells remaining tumorigenic in nude mice (Plattner et al., 1996) . The recent discovery that oncogenic ras activation, in cooperation with the catalytic domain of telomerase and disruption of the intracellular pathway(s) regulated by the large T antigen is sucient to create a human tumor cell (Hahn et al., 1999) and the report of an essential role for ras ± extending beyond the regulation of VEGF expression in vivo ± in the maintenance of solid tumors (Chin et al., 1999) are good indications that downregulation of ras signal transduction may become a valuable tool in tumor therapy.
In summary, our results are the ®rst unambiguous demonstration that a single amino acid change can turn a ras-speci®c GEF, i.e. a protein with oncogenic properties (Egan et al., 1993; Zippel et al., 1994 ) into a Figure 6 The dominant-negative GEF W1056E strongly reduces tumor formation in nude mice. Five-week-old female athimic nu/ nu mice were randomly assigned to each treatment (®ve animals/ group) and challenged subcutaneously in the left inguinal region with 0.2 ml of 0.5, 1 and 2.5610 5 cells in phosphate buered saline. The following cell lines and clones were used: NIH3T3; 226.4.1 cell line; 226.4.1 cells expressing the dominant-negative GEF W1056E (WE.5); 226.4.1 cells expressing the recessive-negative GEF W1056A (WA.10). All the tumors showed comparable histological characteristics and were classi®ed as sarcomas A dominant-negative GEF reverses neoplastic phenotype P Bossu Á et al down-modulator of the transformed phenotype induced by the activated ras oncogene. A mutant in the catalytic domain of CDC25, the S. cerevisiae rasspeci®c GEF, displaying some dominant-negative properties has been described but the ability of the mutant GEF to down-regulate ras signaling in mammalian cells was not tested (Park et al., 1997) . A better understanding of the molecular mechanisms linking down-regulation of the ras pathway to the cell cycle machinery combined with increasingly more powerful gene delivery techniques (see for instance, Mathiesen, 1999) will be required before dominantnegative GEF-derived molecule might be considered as potential therapeutic leads for ras-dependent proliferative disorders. Studies along these lines are currently under way in one of our laboratories.
Materials and methods

Plasmid constructions, cell transfection and cell culture
The whole wild-type and mutant CDC25 Mm ORFs were inserted in the plasmid pcDNA3 (Invitrogen, NV Leek, The Netherlands) under the control of the cytomegalovirus promoter. Control NIH3T3 and a k-ras transformed NIH3T3-derived cell line, 226.4.1 (Pulciani et al., 1985 , obtained through the courtesy of Dr Marco Pierotti (National Cancer Institute, Milan, Italy)) were used throughout this work. Stable cell lines expressing dierent GEF mutants were obtained by transfecting the k-ras transformed 226.4.1 cell line with the calcium phosphate method. Brie¯y, 2610 5 226.4.1 cells were seeded in 100-mm culture dishes in DMEM (Life Technologies Ltd, Paisley, Scotland) containing 10% of calf serum (CS, Colorado Serum Company, Denver, CO, USA) and incubated overnight at 378C in 5% CO 2 . The next day the cells were transfected with 1 mg of plasmid DNA and 30 mg of genomic DNA carrier and incubated overnight at 378C, in 5% CO 2 . After an additional 24 h of incubation, cells were rinsed twice with PBS and fed with DMEM containing 10% CS. As a control, 226.4.1 cells were also transfected with the insertion-less pcDNA3 plasmid. Individual clones resistant to geneticin (G418) were obtained after 15 ± 20 day selection. DNA integration and CDC25 Mm expression was checked by genomic PCR using 50 pmoles of each primer (5'-CGTGATCTGGTGGACAATAACCG 3' and 5' TCGTCTGCTTAGAAACTTTGAGCC 3') and 0.5 units of Taq DNA polymerase (Promega, WI, USA) (data not shown) and immunoprecipitation with anti-CDC25 Mm antibodies, respectively. Morphological analysis of methanol®xed and Giemsa-stained (Sigma, St. Louis, MO, USA) cells was performed with Axioplan optical microscopy (Zeiss, Oberkochen, Germany).
Detection of CDC25
Mm -GEF protein
Control and transfected cells were washed in 20 mM Tris-HCl pH 7.4, 150 mM NaCl (TBS), and harvested in 10 mM TrisHCl pH 7.4, 1 mM EDTA, 0.2 mM AEBSF, 1 mg/ml Aprotinin, 10 mg/ml Leupeptin and 10 mg/ml Pepstatin (lysis buer). Cells were pooled and adjusted at 10 8 cells/ml with lysis buer, then disrupted by 50 strokes in Dounce homogenizer at 48C. After centrifugation at 1000 g the supernatant (S1) was collected and stored at 7808C until use. The total protein concentration was estimated by DC Protein Assay (Bio-Rad, Hercules, CA, USA). For CDC25 Mm immunoprecipitation, to 200 ml of each S1 sample concentrated solutions were added to reach ®nal concentration of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxicholate, 1 mM EDTA, 0.2 mM AEBSF, 10 mg/ml Aprotinin and 10 mg/ml Leupeptin, in 300 ml ®nal volume, then incubated overnight at 48C under gentle shaking with anti-Ras-GRF C-20 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibody. The antigen-antibody complex was precipitated with 30 ml of Protein-G Sepharose (Pharmacia, Uppsala, Sweden). Bound protein was eluted as above and loaded on 8% SDS ± PAGE.
CDC25
Mm protein was detected by Western blotting, with the same antibody used for immunoprecipitation.
Determination of GTP´bound p21
ras Glutathione-Sepharose (Pharmacia) was bound to GST-RBD as described (Taylor, et al., 1996) with minor modi®cations, and stored at 48C until use. S1 from control and transfected cells were prepared as above. The total protein concentration was estimated by DC Protein Assay (Bio-Rad) following the manufacturer's instructions.
For anity precipitation of GTP´bound p21 ras , 200 ml of each S1 sample (corresponding to about 400 ng of total protein) were brought to 20 mM HEPES pH 7.5, 120 mM NaCl, 10% Glycerol, 1.5 mM MgCl 2 , 1 mM EDTA, 100 mM NaF, 1% NP-40, 1 mM AEBSF, 10 mg/ml Aprotinin and 10 mg/ml Leupeptin, in 300 ml ®nal volume, then 30 ml of RBD-bound Glutathione-Sepharose were added. The slurry was incubated 1 h at 48C under gentle shaking, then washed in TBS containing 1% Triton X-100. Bound protein was eluted by adding reducing Laemmli sample buer (Laemmli, 1970) and loaded on 15% SDS ± PAGE. Ras protein was detected by Western blotting, using as primary antibody antik-ras F234 (Santa Cruz Biotechnology).
Flow cytometric analysis of DNA
Starved cells were serum depleted for 18 h; growing cells were obtained by culturing starved cells for additional 36 ± 72 h in the presence of 10% CS.
Cell cycle analysis of control and transfected cells was performed as described (Dolbeare et al., 1983 ) with a FACScan¯ow cytometer (Becton Dickinson, Mountain View, CA, USA). Brie¯y, 30 min before harvesting the cells Bromodeoxyuridine (BrdU, Sigma) was added to the culture medium at the ®nal concentration of 10 mM. Cells were then incubated with an anti-BrdU mouse monoclonal antibody (Becton Dickinson) and labeled with a rabbit FITCconjugated anti-mouse antibody (Becton Dickinson). Cells were then washed twice, incubated for 15 min at 48C with propidium iodide solution (50 mg/ml in 3.4 mM trisodium citrate, 9.65 mM NaCl plus 0.03% Nonidet P40) and analysed by¯ow cytometry. Cell cycle phases were evaluated with the LYSYS II software program.
Soft-agar colony formation analysis
Cell transformation was evaluated with a soft-agar clonogenic assay. Stable transfectants or control cells were plated 1610 4 ± 1610 3 in duplicates in 60-mm tissue culture dishes containing 0.3% top low-melt agarose and 1.5% bottom lowmelt agarose (Bacto agar; Difco, Detroit, MI, USA) supplemented with DMEM 10% CS. Cells were re-fed every 3 ± 4 days with complete medium. After about 3 weeks of incubation colonies were stained with MTT (Sigma) and counted.
Tumorigenicity
Five-week-old female athimic nu/nu mice were purchased from Harlan (Correzzana, Italy). Mice were housed in germfree conditions of controlled temperature (238+18C), humidity (55+10%) and lighting (0700 ± 1900 h), received ad libitum sterilized food pellets and sterilized water containing Josamicine (65 mg/ml) and Gentamicine Sulfate (270 mg/ml) during both acclimation period (1 week) and experiments. All the procedures were performed in the animal facilities according to the ethical guidelines for the conduct of animal research. For tumorigenicity assay mice were randomly assigned to single treatments (®ve animals/group) and challenged subcutaneously in the left inguinal region with 0.2 ml of 0.5, 1 and 2.5610 5 cells in phosphate buered saline. Cages were coded and the size of tumors was evaluated for 42 days by biweekly measurement of the average of two perpendicular diameters of the neoplastic masses with linear caliber. At the end of this time period the mice without tumors were classi®ed as survivors. Latency and survival times were respectively the time period in days to reach a neoplastic mass diameter 43 mm and 410 mm, and the growth was considered the time between the latency and the survival. Tumorigenicity was reported as the per cent of mice with tumors after 6 weeks. For histology, tumor samples were ®xed in formalin and stained with ematoxylin-eosin by standard techniques. All the tumors showed comparable histological characteristics and were classi®ed as sarcomas.
